Ann Rheum Dis: Characteristics associated with COVID-19 hospitalization in patients with rheumatism

Little is known about the outcome of COVID-19 infection in patients with rheumatismThe purpose of this study was to analyze the demographic and clinical studies associated with COVID-19 hospitalization in patients with rheumatismFactorsSelect a series of cases of patients with COVID-19 infection from the COVID-19 Global Rheumatology Alliance register: 24 March 2020 to 20 April 2020ORs and 95% CIs were estimated in hospital using multifactorlogistic regressionAge, sex, smoking status, rheumatism diagnosis, comorbidities and rheumatism medications taken before infection were analyzedIncluded 600 cases from 40 countriesNearly half of the cases were hospitalized (277, 46 per cent) and 55 (9 per cent) diedIn the multi-factor adjustment model, the dose of pernisone of 10 mg/day was associated with an increased chance of hospitalization (OR 2.05, 95% CI 1.06-3.96)Use only conventional disease-improving anti-rheumatic drugs (DMARD) or combinations with biologic/Janus kinase inhibitors is not associated with hospitalization (OR 1.23, 95% CI 0.70-2.17 and OR 0.74, 95% CI 0.37-1.46)The use of nonsteroidal anti-inflammatory drugs is not related to hospitalization status (OR 0.64, 95% CI 0.39-1.06)The use of tumor necrosis factor inhibitors (anti-TNF) is associated with a reduced chance of hospitalization (OR 0.40, 95% CI 0.19-0.81) and not with the use of antimalarial drugs (OR 0.94, 95% CI 0.57-1.57)The study found that in patients with rheumatism, glucocorticoids of 10 mg/day were associated with an increased risk of hospitalization, while anti-TNF was associated with a decrease in the number of hospitalizationsBoth DMARDs and NSAIDs were not associated with an increased chance of hospitalization